{
  "abstract": "Despite the progress made through vaccination campaigns and the use of antivirals, the need for more effective therapeutics to combat respiratory viral infections remains critical. A recent screening of over 2000 repurposed molecules has identified the antibiotic clofoctol (CFT) as a promising candidate for treating COVID-19. However, administering CFT systemically poses challenges due to its low solubility and potential toxicity. In this study, we engineered poly(lactic-co-glycolic) acid (PLGA)-based nanoparticles (NPs) designed to encapsulate high payloads of CFT, allowing for a controlled drug release in the pulmonary environment. Pharmacokinetic studies demonstrated high CFT bioavailability 8 h after intranasal (i.n.) administration. In preclinical models (mouse and hamster) of COVID-19, i.n. administration of CFT-loaded NPs significantly reduced pulmonary viral loads. Remarkably, vectorized CFT also decreased inflammation and improved pathological scores in the lungs. These results pave the way for a groundbreaking CFT formulation designed to tackle the challenges posed by acute respiratory infections. This study marks the first demonstration of a stable, effective and well-tolerated CFT formulation for the treatment of lung diseases.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 17,
  "authors": [
    {
      "name": "Tom Bourguignon"
    },
    {
      "name": "Jesus Alfredo Godinez-Leon"
    },
    {
      "name": "Amine Pochet"
    },
    {
      "name": "Tahmida Shamsuddin"
    },
    {
      "name": "Valentin Sencio"
    },
    {
      "name": "Jonathan Chatagnon"
    },
    {
      "name": "Axelle Grandé"
    },
    {
      "name": "Joan Fine"
    },
    {
      "name": "Séverine Heumel"
    },
    {
      "name": "Cyril Robil"
    },
    {
      "name": "Lou Delval"
    },
    {
      "name": "Catherine Piveteau"
    },
    {
      "name": "Sandrine Belouzard"
    },
    {
      "name": "Priscille Brodin"
    },
    {
      "name": "François Trottein"
    },
    {
      "name": "Arnaud Machelart"
    },
    {
      "name": "Ruxandra Gref"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/939pet0rd8hs9.bib",
  "cited_by": 5,
  "doi": "10.1016/j.ijpharm.2025.125634",
  "fulltext_url": null,
  "id": "939pet0rd8hs9",
  "issns": [
    "0378-5173"
  ],
  "landing_url": "https://hal.science/hal-05805890v1",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "openalex",
      "2740|Inhalation and Respiratory Drug Delivery"
    ]
  ],
  "openalex": "W4409725794",
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-19",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/939pet0rd8hs9.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:59Z",
      "native_id": "hal-05805890",
      "source": "hal",
      "url": "https://hal.science/hal-05805890v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "journal-openalex:3003|Advanced Drug Delivery Systems",
      "subfield": "pharmacology-toxicology"
    }
  ],
  "title": "Pulmonary delivery of clofoctol-loaded nanoparticles inhibits SARS-CoV-2 replication and reduces pneumonia",
  "title_text": "Pulmonary delivery of clofoctol-loaded nanoparticles inhibits SARS-CoV-2 replication and reduces pneumonia",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:59Z",
  "url": "https://research.draconitic.com/paper/939pet0rd8hs9",
  "venue": "International Journal of Pharmaceutics",
  "versions": []
}